Prolonged response to HER2-directed therapy in a patient With HER2-amplified, rapidly progressive metastatic colorectal cancer

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 15, Issue 1, 2017, Pages 3-8

  Parikh, Aparna ^a   Atreya, Chloe ^a   Korn, W Michael ^a   Venook, Alan P ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; B RAF KINASE; BEVACIZUMAB; CAPECITABINE; CARCINOEMBRYONIC ANTIGEN; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; K RAS PROTEIN; NRAS PROTEIN; OXALIPLATIN; PERTUZUMAB; PROTEIN; TRASTUZUMAB; TRASTUZUMAB EMTANSINE; UNCLASSIFIED DRUG; CAMPTOTHECIN; FLUOROURACIL; FOLINIC ACID; MAYTANSINE; MONOCLONAL ANTIBODY; MYC PROTEIN; MYC PROTEIN, HUMAN; PROTEIN P53; TP53 PROTEIN, HUMAN;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CASE REPORT; CHEMORADIOTHERAPY; COLOSTOMY; DRUG RESPONSE; DRUG SUBSTITUTION; FATIGUE; FLUORESCENCE IN SITU HYBRIDIZATION; FUNCTIONAL STATUS; GENE AMPLIFICATION; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LAPAROSCOPIC SURGERY; LIVER BIOPSY; LIVER INJURY; LUNG NODULE; MALE; METASTATIC COLORECTAL CANCER; MIDDLE AGED; NEXT GENERATION SEQUENCING; RECTUM HEMORRHAGE; ADJUVANT CHEMORADIOTHERAPY; ANALOGS AND DERIVATIVES; BIOPSY; COLORECTAL NEOPLASMS; DISEASE COURSE; DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE; ECHOGRAPHY; GENETICS; HIGH THROUGHPUT SEQUENCING; LAPAROSCOPY; LIVER NEOPLASMS; MOLECULARLY TARGETED THERAPY; OFF LABEL DRUG USE; PALLIATIVE THERAPY; PATHOLOGY; PROCEDURES; SECONDARY; X-RAY COMPUTED TOMOGRAPHY;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOPSY; CAMPTOTHECIN; CHEMORADIOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE, NEOPLASM; FLUOROURACIL; GENE AMPLIFICATION; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; LAPAROSCOPY; LEUCOVORIN; LIVER NEOPLASMS; MALE; MAYTANSINE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; OFF-LABEL USE; PALLIATIVE CARE; PROTO-ONCOGENE PROTEINS C-MYC; RECEPTOR, ERBB-2; TOMOGRAPHY, X-RAY COMPUTED; TUMOR SUPPRESSOR PROTEIN P53; ULTRASONOGRAPHY;

EID: 85009142167     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2017.0002     Document Type: Article

References (28)

1. Hudis CA. Trastuzumab-mechanism of action and use in clinical practice. N Engl J Med 2007;357: 39-51.
2. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial. Lancet 2010;376: 687-697.
3. Swain SM, Kim SB, Cortes J, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): Overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol 2013;14: 461-471.
4. Vakiani E. HER2 testing in gastric and gastroesophageal adenocarcinomas. Adv Anat Pathol 2015;22: 194-201.
5. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial. Lancet 2010;376: 687-697.
6. Lee WS, Park YH, Lee JN, et al. Comparison of HER2 expression between primary colorectal cancer and their corresponding metastases. Cancer Med 2014;3: 674-680.
7. Valtorta E, Martino C, Sartore-Bianchi A, et al. Assessment of a HER2 scoring system for colorectal cancer: Results from a validation study. Mod Pathol 2015;28: 1481-1491.
8. Seo AN, Kwak Y, Kim DW, et al. HER2 status in colorectal cancer: Its clinical significance and the relationship between HER2 gene amplification and expression. PloS One 2014;9: E98528.
9. Siena A, Sartore-Bianchi A, Lonardi S, et al. Trastuzumab and lapatinib in HER2-amplified metastatic colorectal cancer patients (mCRC): The HERACLES trial [abstract]. J Clin Oncol 2015;33(Suppl): Abstract 3508.
10. Kavuri SM, Jain N, Galimi F, et al. HER2 activating mutations are targets for colorectal cancer treatment. Cancer Discov 2015;5: 832-841.
11. Hurwitz H, Hainsworth JD, Swanton C, et al. Targeted therapy for gastrointestinaI (GI) tumors based on molecular profiles: Early results from MyPathway, an open-label phase IIa basket study in patients with advanced solid tumors [abstract]. J Clin Oncol 2016;34(Suppl 4S): Abstract 653.
12. Marx AH, Burandt EC, Choschzick M, et al. Heterogenous high-level HER-2 amplification in a small subset of colorectal cancers. Human Pathol 2010;41: 1577-1585.
13. Bose R, Ali S, Jain N, et al. Frequency of HER2 mutations and amplification in GI malignancies and ability of pertuzumab to overcome neuregulin1 mediated drug resistance to a HER2 tyrosine kinase inhibitor in colon cancer [abstract]. J Clin Oncol 2016;34(Suppl 4S): Abstract 630.
14. Park DI, Kang MS, Oh SJ, et al. HER-2/neu overexpression is an independent prognostic factor in colorectal cancer. Int J Colorectal Dis 2007;22: 491-497.
15. Perez EA, Jenkins RB, Dueck AC, et al. C-MYC alterations and association with patient outcome in early-stage HER2-positive breast cancer from the north central cancer treatment group N9831 adjuvant trastuzumab trial. J ClinOncol 2011;29: 651-659.
16. Vlacich G, Coffey RJ. Resistance to EGFR-targeted therapy: A family affair. Cancer Cell 2011;20: 423-425.
17. Bertotti A, Papp E, Jones S, et al. The genomic landscape of response to EGFR blockade in colorectal cancer. Nature 2015;526: 263-267.
18. Yonesaka K, Zejnullahu K, Okamoto I, Satoh T. Activation of ERBB2 signaling causes resistance to the EGFR-y. Sci Transl Med 2011;3: 99ra86.
19. Bertotti A, Migliardi G, Galimi F, et al. A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer Discov 2011;1: 508-523.
20. Leto SM, Sassi F, Catalano I, et al. Sustained inhibition of HER3 and EGFR is necessary to induce regression of HER2-amplified gastrointestinal carcinomas. Clin Cancer Res 2015;21: 5519-5531.
21. Ramanathan RK, Hwang JJ, Zamboni WC, et al. Low overexpression of HER-2/neu in advanced colorectal cancer limits the usefulness of trastuzumab (Herceptin) and irinotecan as therapy. A phase II trial. Cancer Invest 2004;22: 858-865.
22. Clark JW ND, Hollis D, Mayer R. Phase-II trial of 5-fluororuacil (5-FU), leucovorin (LV), oxaliplatin (Ox), and trastuzumab (T) for patients with metastatic colorectal cancer (CRC) refractory to initial therapy. Onkologie 2003;26(Suppl 3): 13-46.
23. FDA Approval for Lapatinib Ditosylate. National Cancer Institute Web site. Available at: Http://www.cancer.gov/about-cancer/treatment/drugs/fda-lapatinib. Accessed April 21, 2016.
24. Deeken JF, Wang H, Subramaniam D, et al. A phase 1 study of cetuximab and lapatinib in patients with advanced solid tumor malignancies. Cancer 2015;121: 1645-1653.
25. Barok M, Joensuu H, Isola J. Trastuzumab emtansine: Mechanisms of action and drug resistance. Breast Cancer Res 2014;16: 209.
26. Junttila TT, Li G, Parsons K, et al. Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer. Breast Cancer Res Treat 2011;128: 347-356.
27. Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 2012;367: 1783-1791.
28. Siena S, Bardelli A, Sartore-Bianchi A, et al. HER2 amplification as a 'molecular bait' for trastuzumab-emtansine (T-DM1) precision chemotherapy to overcome anti-HER2 resistance in HER2 positive metastatic colorectal cancer: The HERACLES-RESCUE trial [abstract]. J Clin Oncol 2016;34(Suppl 4S): Abstract TPS774.